Skip to main content
. 2019 Nov 26;9:1256. doi: 10.3389/fonc.2019.01256

Table 3b.

TEAEs leading to dose reduction, interruption, or discontinuation in the delayed nivolumab cohort.

Parameter, n (%) Delayed cohort (dose-finding part only) (n = 10)
nab-Paclitaxel Carboplatin Nivolumab nab-Paclitaxel/carboplatin/nivolumab
Patients with ≥1 TEAE leading to dose reduction or interruptiona 8 (80.0) 6 (60.0) 1 (10.0) 8 (80.0)
Patients with ≥1 TEAE leading to withdrawal of study drug 1 (10.0) 1 (10.0) 2 (20.0) 2 (20.0)
Most common TEAEs leading to dose reduction and/or interruptionb
   Neutropenia
4 (40.0) 2 (20.0) 0 4 (40.0)
   Platelet count decreased 2 (20.0) 1 (10.0) 0 2 (20.0)
   Fatigue 2 (20.0) 1 (10.0) 0 2 (20.0)
Most common TEAEs leading to withdrawal of study drugc
   Myelopathy
0 0 1 (10.0) 1 (10.0)
   Pneumonitis 0 0 1 (10.0) 1 (10.0)
   Platelet count decreased 1 (10.0) 1 (10.0) 0 1 (10.0)

TEAE, treatment-emergent adverse event.

a

For nivolumab, because dose reductions were not allowed, the numbers represent patients with dose interruption.

b

Occurring in >1 patient in any group, presented in descending order of incidence in the nab-paclitaxel/carboplatin/nivolumab group.

c

Due to small numbers, all TEAEs leading to withdrawal are listed.